Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 56 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
KiOmed Pharma from Herstal, company number BE0846318862, closed financial year 2025 with a result of € 2.2 million after tax. For that financial year KiOmed Pharma recorded a gross margin of € 8 million and equity of € 9 million. Compared with financial year 2024, the result moved from € -3 million to € 2.2 million. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 2, 2026.
€ 9 million
▲ 107% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 2.2 million
▲ still € 3 million loss in 2024
Profit after tax over the fiscal year.
€ 257,137
▼ 78% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € -8.8 million.
People and assets in 2025
30.2
▼ 2.8 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 3.2 million
▼ 2% vs 2024
€ 104,900 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 186,022
▼ 29% vs 2024
Of which on lease € 0.
Debts at end 2025
€ 5.1 million
▼ 55% vs 2024
€ 1.4 million is repaid this year. At this pace the long-term loan is gone in ≈ 4 years.
€ 2.1 million
▼ 13% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 438,670
▲ 8% vs 2024
Wages, holiday pay and social contributions still to pay. No outstanding taxes.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Revenue | € 9,249,550 | - | - | - | |
| Gross margin | - | € -767,261 | € 2,976,882 | € 8,016,541 | ▲ 169% |
| Profit after taxes | € 2,966,641 | € -5,086,309 | € -2,980,196 | € 2,185,530 | ▲ € 5.2 million |
| Equity | € 9,159,749 | € 5,294,345 | € 4,351,952 | € 9,021,523 | ▲ 107% |
| Total debts | € 6,123,332 | € 13,583,488 | € 18,295,760 | € 10,614,440 | ▼ 42% |
| Cash | € 1,683,714 | € 982,214 | € 1,154,317 | € 257,137 | ▼ 78% |
| Land & buildings | € 1,086,147 | € 1,012,095 | € 938,043 | € 864,250 | ▼ 8% |
| Retained profit | € -2,958,113 | € -8,044,422 | € -11,024,618 | € -8,839,088 | ▲ € 2.2 million |
| Bank debt | € 3,240,061 | € 7,202,543 | € 11,450,346 | € 5,128,520 | ▼ 55% |
| Balance sheet total | € 15,283,080 | € 18,892,556 | € 22,662,436 | € 19,658,593 | ▼ 13% |
| Employees (FTE) | 19.6 | 29.2 | 33 | 30.2 | ▼ 2.8 |
Key figures of KiOmed Pharma, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to KiOmed Pharma?
What happened at KiOmed Pharma in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 2.2 million. Source: NBB ↗
- New establishment in Liège. KBO
- Start of the company according to the CBE. KBO
- New establishment in Herstal. KBO
In short
From € 3 million profit in 2022 to € 2.2 million profit in 2025.
Paid € 7,035 in corporate taxes since 2022.
Best year ever: 2022, with € 3 million profit.
On average € 265,400 of value added per employee in 2025.
A new publication or filing at KiOmed Pharma? We notify you, reason included.
Follow KiOmed PharmaDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Establishments
Establishment units
Physical locations of this company
Rue Haute Claire 4
4041 Herstal
Boulevard de Patience et Beaujonc 3
4000 Liège
Active since 1 February 2024
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0846.318.862
- VAT number
- BE 0846.318.862
- Registered office
- Rue Haute Claire 4, 4041 Herstal
- Names & denominations
- KiOmed Pharma
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 4 June 2012
- Peppol
- Active · Active since 12 Sept 2025
- Activities · NACE
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Niet-gespecialiseerde groothandel